Zimmer Biomet net sales up 9.3% to USD 2.087B in Q1 2026

Zimmer Biomet Holdings, Inc. reported financial results for the quarter ended March 31, 2026. The Company reported first quarter net sales of $2.087 billion, an increase of 9.3% over the prior year period, an increase of 6.8% on a constant currency1 basis and an increase of 2.9% on an organic constant currency1 basis. Net earnings for the first quarter were $238.1 million, or $409.4 million on an adjusted1 basis.

Diluted earnings per share were $1.22 for the first quarter, an increase of 34.1%, and adjusted1 diluted earnings per share were $2.09, an increase of 15.5%. Zimmer Biomet generated $359.4 million in operating cash flow and $245.9 million of free cash flow in the first quarter.

“We are off to a solid start to the year — strategically, operationally and financially,” said Ivan Tornos, Chairman, President and CEO of Zimmer Biomet. “Our first quarter results reflect healthy end markets, continued momentum from our recently launched products and disciplined execution across the business. Given our progress and with our go-to-market transformation proceeding as planned, we are raising our adjusted EPS guidance and free cash flow expectations for the year. We remain confident that our strategy will position Zimmer Biomet for consistent, durable growth over the longer term.”

Geographic and product category sales
The following sales table provides results by geography and product category for the three-month period ended March 31, 2026, as well as the percentage change compared to the prior year period, on both a reported basis and a constant currency basis. Percentage change is also presented on an organic constant currency basis to exclude the impact on net sales from the April 2025 acquisition of Paragon 28, Inc.

Financial guidance
The Company is updating its full-year 2026 financial guidance as follows:

MB Bureau